ASX - By Stock
|
IIQ |
Re:
Ann: INOVIQ Investor Update
|
|
F18FDG
|
14 |
4.2K |
2 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
14
|
4.2K
|
2
|
|
ASX - By Stock
|
EIQ |
Re:
Ann: Management Update
|
|
F18FDG
|
15 |
3.8K |
0 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
15
|
3.8K
|
0
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene and Kincell Bio Announce Strategic Partnership
|
|
F18FDG
|
144 |
60K |
32 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
144
|
60K
|
32
|
|
ASX - By Stock
|
CUV |
Re:
Clinuvel and Hedge Fund Manipulation
|
|
F18FDG
|
18 |
5.1K |
1 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
18
|
5.1K
|
1
|
|
ASX - By Stock
|
VBS |
Re:
Ann: Half Year Report & Appendix 4D
|
|
F18FDG
|
1 |
355 |
0 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
1
|
355
|
0
|
|
ASX - By Stock
|
ADR |
Re:
Ann: Rimidi Partnership for Respiratory Clinical Management
|
|
F18FDG
|
12 |
3.4K |
3 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
12
|
3.4K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Patent Granted in Israel for RECCE Anti-Infectives
|
|
F18FDG
|
8 |
2.8K |
4 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
8
|
2.8K
|
4
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Trading Halt
|
|
F18FDG
|
32 |
13K |
1 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
32
|
13K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix to Acquire ARTMS (Isotope Production Platform)
|
|
F18FDG
|
43 |
16K |
7 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
43
|
16K
|
7
|
|
ASX - By Stock
|
ALA |
Re:
onCARlytics update
|
|
F18FDG
|
4 |
1.3K |
1 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
4
|
1.3K
|
1
|
|
ASX - By Stock
|
ADR |
Re:
Ann: Adherium receives $1.5m Australian R&D Tax Rebate
|
|
F18FDG
|
3 |
1.4K |
2 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
3
|
1.4K
|
2
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Phase 1 onCARlytics Trial Advances to Combination Arm
|
|
F18FDG
|
147 |
62K |
9 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
147
|
62K
|
9
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Phase 1 onCARlytics Trial Advances to Combination Arm
|
|
F18FDG
|
147 |
62K |
23 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
147
|
62K
|
23
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Phase 1 onCARlytics Trial Advances to Combination Arm
|
|
F18FDG
|
147 |
62K |
17 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
147
|
62K
|
17
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix to Acquire ARTMS (Isotope Production Platform)
|
|
F18FDG
|
43 |
16K |
9 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
43
|
16K
|
9
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
F18FDG
|
668 |
266K |
4 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
668
|
266K
|
4
|
|
ASX - By Stock
|
ADR |
Re:
Ann: Alliance Tech Medical Partnership to expand US product reach
|
|
F18FDG
|
14 |
4.2K |
4 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
14
|
4.2K
|
4
|
|
ASX - By Stock
|
SNT |
Re:
Ann: SNT to Trial New Cancer Indication Following MRFF Grant
|
|
F18FDG
|
8 |
3.0K |
0 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
8
|
3.0K
|
0
|
|
ASX - By Stock
|
CDX |
Re:
Ann: ASX Relisting and Market Update
|
|
F18FDG
|
76 |
18K |
1 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
76
|
18K
|
1
|
|
ASX - By Stock
|
DVL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
F18FDG
|
3 |
968 |
1 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
3
|
968
|
1
|
|
ASX - By Stock
|
DVL |
Re:
Ann: Results of Annual General Meeting
|
|
F18FDG
|
7 |
1.5K |
0 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
7
|
1.5K
|
0
|
|
ASX - By Stock
|
DVL |
Re:
Ann: dorsaVi signs new multi-year contracts in the US market
|
|
F18FDG
|
10 |
3.1K |
0 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
10
|
3.1K
|
0
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Radiopharm receives $1.9 M advance on FY24 R&D tax incentive
|
|
F18FDG
|
4 |
1.0K |
0 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
4
|
1.0K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
VIRALEZE™ nasal spray a blow for covid
|
|
F18FDG
|
37 |
6.0K |
2 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
37
|
6.0K
|
2
|
|
ASX - By Stock
|
CDX |
Re:
Ann: CDX January 2024 Webinar Presentation
|
|
F18FDG
|
9 |
3.9K |
2 |
25/01/24 |
25/01/24 |
ASX - By Stock
|
9
|
3.9K
|
2
|
|
ASX - By Stock
|
CDX |
Re:
Ann: CDX January 2024 Webinar Presentation
|
|
F18FDG
|
9 |
3.9K |
1 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
9
|
3.9K
|
1
|
|
ASX - By Stock
|
CDX |
Re:
Ann: CDX January 2024 Webinar Presentation
|
|
F18FDG
|
9 |
3.9K |
2 |
18/01/24 |
18/01/24 |
ASX - By Stock
|
9
|
3.9K
|
2
|
|
ASX - By Stock
|
AT1 |
Re:
Ann: Final Director's Interest Notice - C LaBelle
|
|
F18FDG
|
13 |
5.3K |
0 |
16/01/24 |
16/01/24 |
ASX - By Stock
|
13
|
5.3K
|
0
|
|
ASX - By Stock
|
ADO |
Re:
2024 - The year of ADO
|
|
F18FDG
|
691 |
219K |
9 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
691
|
219K
|
9
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Proposed issue of securities - ALA
|
|
F18FDG
|
1 |
658 |
0 |
08/01/24 |
08/01/24 |
ASX - By Stock
|
1
|
658
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Chimeric to present at Biotech Showcase at JPM week
|
|
F18FDG
|
19 |
7.0K |
2 |
21/12/23 |
21/12/23 |
ASX - By Stock
|
19
|
7.0K
|
2
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Europe Patent to be Granted for PD1-Vaxx Cancer Vaccine
|
|
F18FDG
|
104 |
39K |
10 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
104
|
39K
|
10
|
|
ASX - By Stock
|
TGH |
Re:
Ann: TGH 2023 AGM Results of Meeting
|
|
F18FDG
|
1 |
605 |
4 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
1
|
605
|
4
|
|
ASX - By Stock
|
TGH |
Re:
Ann: Initial Director's Interest Notice
|
|
F18FDG
|
2 |
566 |
0 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
2
|
566
|
0
|
|
ASX - By Stock
|
NSB |
Re:
Ann: Changes to NSB Board
|
|
F18FDG
|
7 |
2.7K |
0 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
7
|
2.7K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil gaining traction in the Israeli healthcare market
|
|
F18FDG
|
6 |
2.4K |
2 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
6
|
2.4K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil onboards first patient in PANCOSIL Clinical Trial
|
|
F18FDG
|
19 |
5.3K |
1 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
19
|
5.3K
|
1
|
|
ASX - By Stock
|
MEM |
Re:
Out with the old, In with the new
|
|
F18FDG
|
4 |
1.2K |
1 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
4
|
1.2K
|
1
|
|
ASX - By Stock
|
MEM |
Re:
Ann: Board and executive transition and capital raise
|
|
F18FDG
|
12 |
3.6K |
1 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
12
|
3.6K
|
1
|
|
ASX - By Stock
|
NSB |
Re:
Ann: Changes to NSB Board
|
|
F18FDG
|
7 |
2.7K |
2 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
7
|
2.7K
|
2
|
|
ASX - By Stock
|
NSB |
Re:
Ann: Resignation of CEO
|
|
F18FDG
|
27 |
12K |
1 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
27
|
12K
|
1
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Update on ALA-101 and onCARlytics research collaboration
|
|
F18FDG
|
12 |
5.0K |
0 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
12
|
5.0K
|
0
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Notification regarding unquoted securities - RAD
|
|
F18FDG
|
1 |
694 |
0 |
03/12/23 |
03/12/23 |
ASX - By Stock
|
1
|
694
|
0
|
|
ASX - By Stock
|
EPN |
Re:
Ann: Termination of Chief Executive Officer
|
|
F18FDG
|
10 |
3.4K |
2 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
10
|
3.4K
|
2
|
|
ASX - By Stock
|
EPN |
Re:
Ann: Termination of Chief Executive Officer
|
|
F18FDG
|
10 |
3.4K |
0 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
10
|
3.4K
|
0
|
|
ASX - By Stock
|
CDX |
Re:
Ann: Finance Facility and Creditor Restructure Update
|
|
F18FDG
|
46 |
10K |
2 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
46
|
10K
|
2
|
|
ASX - By Stock
|
EPN |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
F18FDG
|
21 |
10K |
2 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
21
|
10K
|
2
|
|
ASX - By Stock
|
EPN |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
F18FDG
|
21 |
10K |
2 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
21
|
10K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Entitlement Offer closing date extended to 30 November 2023
|
|
F18FDG
|
29 |
9.2K |
2 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
29
|
9.2K
|
2
|
|
ASX - By Stock
|
IMU |
Re:
Ann: FDA Fast Track Designation Granted for VAXINIA Trial Program
|
|
F18FDG
|
412 |
169K |
0 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
412
|
169K
|
0
|
|